Patients
Clinical Trials and Research

AllRock Bio is a clinical-stage biotechnology company developing an oral pan-ROCK inhibitor for pulmonary arterial hypertension.
allrockbio.comCrawled Nov 2, 2026
Clinical Trials and Research
A Phase 1 trial showed that daily ROC-101 dosing achieved plasma exposures predicted to inhibit ROCK1 and ROCK2 isoforms, reducing ROCK activity and inflammatory cytokine secretion by PBMCs.
AllRock Bio’s lead drug, ROC-101, is an investigational oral pan-ROCK inhibitor designed to promote vasodilation, reduce vascular remodeling, and improve endothelial function.
AllRock Bio received funding to advance its pan-ROCK inhibitor ROC-101 through Phase 2a testing in pulmonary arterial hypertension (PAH) and interstitial lung disease-associated PAH (ILD-PH) patients. Topline data from the ROC-101 Phase 1 study showed favorable safety and tolerability, with no associated hypotension.
The Phase 2a ROCSTAR study evaluates ROC-101, an oral pan-ROCK inhibitor, in PAH and ILD-PH patients alongside standard therapies, including sotatercept.
ROC-101 demonstrates favorable pharmacokinetics for once-daily dosing, supporting its potential therapeutic efficacy in PAH and ILD-PH. The company plans to begin a Phase 2 proof-of-concept trial in Q4 2025, with funding to advance the pan-ROCK inhibitor through Phase 2a testing.
AllRock Bio, Inc. is dedicated to advancing novel therapies to improve the lives of patients suffering from pulmonary hypertension, interstitial lung diseases, and other fibrotic conditions.
AllRock Bio invites inquiries about its ROCSTAR study.
AllRock Bio is leveraging extensive expertise from drug development to commercialization. AllRock Bio’s team is dedicated to advancing impactful therapies for cardiopulmonary diseases.
AllRock Bio begins dosing patients in its Phase 2a ROCSTAR trial of the experimental drug ROC-101, targeting pulmonary hypertension. The trial marks the first human testing of ROC-101, a potential treatment for a rare and progressive cardiovascular condition. Researchers evaluate safety and preliminary efficacy in early-stage participants.
AllRock Bio presents Phase 1 clinical trial results for ROC-101, its first-in-class oral inhibitor targeting pan-rho-associated protein kinase (ROCK). The data is shared at the European Respiratory Society (ERS) Congress, highlighting early-stage progress in drug development for respiratory conditions. ROC-101 represents a novel approach in targeting ROCK pathways.
Allrock Bio secures $50 million in funding to advance **ROC-101**, an oral therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension due to interstitial lung disease (PH-ILD). The **ROCSTAR trial** will evaluate ROC-101 in combination with standard treatments, with enrollment set to begin in late 2025. The trial targets patients with PAH and PH-ILD, two severe and progressive forms of pulmonary hypertension.
AllRock Bio secures $50 million in Series A funding to develop therapies for cardiopulmonary and fibrotic diseases. The clinical-stage biotech company aims to advance treatments targeting conditions like heart and lung disorders. Investors back the company’s research pipeline focused on addressing unmet medical needs in fibrosis-related illnesses.
Former CinCor Pharmaceuticals executives have founded AllRock Bio, a new biotech startup. The company licenses a drug from Sanofi targeting pulmonary arterial hypertension for clinical testing.
AllRock Bio secures a $50 million Series A funding round co-led by Versant Ventures and Westlake BioPartners. The company advances its lead clinical program targeting pulmonary hypertension, a cardiopulmonary disease. This funding supports further development of therapies for cardiopulmonary and fibrotic diseases.